 Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor VEGFR, so it can inhibit tumor angiogenesis. This phase I study aims to determine the drugs toxicity and to find a dose level to be used in a phase II study in solid tumor patients. 